FilingsTodayJeil Pharma Holdings
At a glance
Jeil Pharma Holdings filed 23 disclosures in the last 12 months, including 4 insider and 3 5% holder. The most recent key filing was on Jul 15.
Revenue for 2025 was ₩658B, down 15.7% on 2024. Operating margin was 5.9% against -1.5% a year earlier. Debt was 87% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩315B and operating loss of ₩6.4B.
The 2025 annual report lists 40 employees with an average tenure of 11.6 years and average pay of ₩73.4M. Its 7 directors and auditors were paid ₩131.2M each on average. It paid ₩70 per common share in cash dividends, against ₩50 a year earlier (+40%). 한승수 and related parties held 73.16% at year end.
From the 2025 annual report
Staff: 40 (25 men, 15 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩2.9B. Directors and auditors: 7, paid ₩918.2M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩70 | ₩50 | ₩50 |
| Payout ratio | 3.1% | - | - |
| Yield (as filed) | 0.90% | 0.60% | 0.40% |
| Total cash dividends | ₩1.1B | ₩183M | ₩768M |
Largest shareholder
한승수 holds 57.80%; with 6 related parties the group holds 73.16% of common shares at year end.
Auditor: 대주회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.